WuXi Apptec: Investor Day Takeaways: Commercial orders and capacity expansion broaden revenue visibility while AIDD creates more demand for wet-lab

We attended WuXi AppTec's Investor Day on site and visited its small molecule and GLP-1 manufacturing facilities in TaiXing on Friday (6 Nov). We were impressed by the breadth of its integrated discovery and manufacturing platform, its ability to develop manufacturing processes for complex molecules, and its employees' loyalty to the company and sense of responsibility. AIDD (AI-driven drug discovery) is generating significant new demand for wet-lab work at WuXi Testing and WuXi Biology, while lab automation is becoming a differentiated feature of WuXi Testing and WuXi Biology. WuXi Chemistry not only has very solid enzyme-based biocatalysis and flow chemistry capabilities, but also confirms its commercial portfolio includes three GLP-1 programs, three KRAS programs, and at least one oral PCSK9 program. WuXi Apptec remains one of our top picks in the China CXO space. Management sees AI expanding the number of drug hypotheses, targets, and modalities that clients can pursue, each requir